The clinical studies on a new drug designed to treat high blood pressure seem to have been manipulated by the first company that tested the product in Japan. The drug in question is called Diovan and is produced by a global pharmaceutical company, Novartis Pharma.
Jikei University, a medical school in Tokyo, announced on Tuesday the preliminary results of a probe into a study by its researchers on the effects of the drug, Diovan.
According to the panel of experts their results do not match the preliminary chart, filled after the first set of tests. The panel believes the data was not altered by the school’s researchers. It says the analysis was carried out by a former official of Novartis Pharma, the media writes. Also, another problem with the paperwork of this drug is that the researchers falsely reported that the pharmaceutical company did not participate in the study.
The former company official is said to have been involved in clinical tests of Diovan at a number of medical schools.
Earlier this month, Kyoto Prefectural University of Medicine said its clinical study may have wrongly concluded that the drug is more effective than other medications in reducing brain strokes and angina.
Novartis Pharma used the results of the clinical study to promote Diovan – a drug that has annual sales of about $ 1 billion.